National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 22694 [2014-09224]
Download as PDF
<![CDATA[
22694
Federal Register / Vol. 79, No. 78 / Wednesday, April 23, 2014 / Notices
Data.’’ This report summarizes findings
and recommendations from eight FDA
working groups established to enhance
the transparency and public
accessibility of the Agency’s compliance
and enforcement data.
Dated: April 17, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–09188 Filed 4–22–14; 8:45 am]
Dated: April 17, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4164–01–P
[FR Doc. 2014–09224 Filed 4–22–14; 8:45 am]
BILLING CODE 4140–01–P
FOR FURTHER INFORMATION CONTACT:
Daniel W. Sigelman, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, rm. 4254, Silver Spring,
MD 20993, 301–796–4706, FAX: 301–
847–8616, email: daniel.sigelman@
fda.hhs.gov.
FDA is
announcing the availability of a report
entitled ‘‘FDA Transparency Initiative:
Increasing Public Access to FDA’s
Compliance and Enforcement Data.’’
FDA is responsible for a broad range of
compliance and enforcement activities.
Increasing the transparency of these
activities enhances the public’s
understanding of the Agency’s decisions
and promotes accountability of the
Agency and the regulated industry.
On October 3, 2011, FDA issued a
report entitled, ‘‘Food and Drug
Administration Transparency Initiative:
Draft Proposals for Public Comment to
Increase Transparency by Promoting
Greater Access to the Agency’s
Compliance and Enforcement Data.’’
The report advanced eight draft
proposals for making FDA’s publicly
available compliance and enforcement
data more accessible and user-friendly
(available at: https://www.fda.gov/
downloads/AboutFDA/Transparency/
TransparencyInitiative/
UCM273145.pdf). Following extensive
public comment on the report and
internal FDA deliberation, the FDA
Commissioner adopted all eight draft
proposals, committing FDA to exploring
numerous avenues for increasing the
transparency and public accessibility of
its compliance and enforcement data
(see 77 FR 5027, February 1, 2012, and
https://www.fda.gov/AboutFDA/
Transparency/TransparencyInitiative/
ucm289638.htm).
To develop plans for addressing the
eight initiatives, FDA established eight
working groups with representatives
from all of FDA’s centers and several of
its offices. Each group was asked to draft
a report on its initiative and to include
recommendations for moving forward.
These efforts culminated in the
preparation of this report, which
summarizes the eight initiatives and the
recommendations from the relevant
working groups for enhancing the
transparency and public accessibility of
FDA’s compliance and enforcement
data.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
wreier-aviles on DSK5TPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
15:37 Apr 22, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
of Scientific Counselors, National
Institute of Biomedical Imaging and
Bioengineering.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Biomedical Imaging
and Bioengineering, including
consideration of personal qualifications
and performance, and the competence
of individual investigators, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: Board of Scientific
Counselors, National Institute of Biomedical
Imaging and Bioengineering.
Date: June 1, 2014.
Time: 7:30 p.m. to 9:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Date: June 2, 2014.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 10, 10 Center Drive, Bethesda, MD
20892.
Date: June 3, 2014.
Time: 8:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Richard D. Leapman,
Intramural Scientific Director, National
Institute of Biomedical Imaging, and
Bioengineering, Bethesda, MD 20892, 301–
496–2599, leapmanr@mail.nih.gov.
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Special
Topic: R21 Re-review.
Date: April 24, 2014.
Time: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: David B Winter, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4204,
MSC 7812, Bethesda, MD 20892, 301–435–
1152, dwinter@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: AIDS and AIDS Related Research.
Date: April 28, 2014.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Mary Clare Walker, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5208,
MSC 7852, Bethesda, MD 20892, (301) 435–
1165, walkermc@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
E:\FR\FM\23APN1.SGM
23APN1
]]>Agencies
[Federal Register Volume 79, Number 78 (Wednesday, April 23, 2014)]
[Notices]
[Page 22694]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09224]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Board of Scientific Counselors, National Institute of Biomedical
Imaging and Bioengineering.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Biomedical Imaging and Bioengineering, including
consideration of personal qualifications and performance, and the
competence of individual investigators, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, National
Institute of Biomedical Imaging and Bioengineering.
Date: June 1, 2014.
Time: 7:30 p.m. to 9:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Date: June 2, 2014.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 10, 10 Center
Drive, Bethesda, MD 20892.
Date: June 3, 2014.
Time: 8:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Richard D. Leapman, Intramural Scientific
Director, National Institute of Biomedical Imaging, and
Bioengineering, Bethesda, MD 20892, 301-496-2599,
leapmanr@mail.nih.gov.
Dated: April 17, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-09224 Filed 4-22-14; 8:45 am]
BILLING CODE 4140-01-P
